FATE - Fate Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
FATE price evolution
FATE
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.05 | $48.51 | $61.98 | $57.25 |
| Short term investments | $273.31 | $316.4 | $331.13 | $366.88 |
| Net receivables | $1.83 | $1.54 | $2.83 | $13.5 |
| Inventory | ||||
| Total current assets | $331.54 | $364.17 | $392.18 | $437.89 |
| Long term investments | $0.98 | $7.29 | $3.91 | |
| Property, plant & equipment | $158.51 | $164.43 | $170.07 | $173.28 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $174.68 | $179.61 | $192.57 | $192.45 |
| Total investments | $274.29 | $316.4 | $338.42 | $370.79 |
| Total assets | $506.22 | $543.79 | $584.76 | $630.34 |
| Current liabilities | ||||
| Accounts payable | $4.72 | $5.71 | $7.51 | $9.86 |
| Deferred revenue | $0.69 | $1.11 | $1.93 | $1.74 |
| Short long term debt | $6.18 | $5.98 | $5.79 | $5.54 |
| Total current liabilities | $39.09 | $41.33 | $44.69 | $48.65 |
| Long term debt | $97.36 | $98.98 | $100.56 | $102.07 |
| Total noncurrent liabilities | $98.71 | $99.68 | $102.31 | $104.21 |
| Total debt | $103.54 | $104.95 | $106.35 | $107.61 |
| Total liabilities | $137.8 | $141.01 | $147 | $152.86 |
| Shareholders' equity | ||||
| Retained earnings | -$1211.73 | -$1167.61 | -$1122.44 | -$1069.68 |
| Other shareholder equity | $0.01 | -$0.5 | -$0.59 | -$0.65 |
| Total shareholder equity | $368.42 | $402.78 | $437.75 | $477.47 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.05 | $76.56 | $148.81 | $182.57 |
| Short term investments | $273.31 | $374.89 | $482.33 | $315.57 |
| Net receivables | $1.83 | $38.48 | $8.68 | $5.51 |
| Inventory | ||||
| Total current assets | $331.54 | $502.07 | $633.41 | $494.32 |
| Long term investments | $0.98 | $4.94 | $100.66 | |
| Property, plant & equipment | $158.51 | $176.09 | $162.25 | $99.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $174.68 | $203.49 | $288.04 | $128.13 |
| Total investments | $274.29 | $379.84 | $582.99 | $315.57 |
| Total assets | $506.22 | $705.56 | $921.46 | $622.46 |
| Current liabilities | ||||
| Accounts payable | $4.72 | $8.27 | $8.61 | $6.28 |
| Deferred revenue | $0.69 | $42.23 | $48.61 | $67.17 |
| Short long term debt | $6.18 | $5.63 | $5.58 | $3.35 |
| Total current liabilities | $39.09 | $114.05 | $81.28 | $85.56 |
| Long term debt | $97.36 | $103.71 | $109.24 | $93.94 |
| Total noncurrent liabilities | $98.71 | $107.57 | $161.33 | $152.45 |
| Total debt | $103.54 | $109.34 | $114.82 | $97.3 |
| Total liabilities | $137.8 | $221.62 | $242.62 | $238.01 |
| Shareholders' equity | ||||
| Retained earnings | -$1211.73 | -$1050.8 | -$769.08 | -$556.93 |
| Other shareholder equity | $0.01 | -$1.85 | -$0.76 | $0.07 |
| Total shareholder equity | $368.42 | $483.94 | $678.84 | $384.44 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.68 | $1.94 | $0.93 | $58.98 |
| Cost of revenue | ||||
| Gross Profit | $1.68 | $1.94 | $0.93 | $58.98 |
| Operating activities | ||||
| Research & development | $31.82 | $34.27 | $40.88 | $65.63 |
| Selling, general & administrative | $17.93 | $18.95 | $22.62 | $21.94 |
| Total operating expenses | $49.75 | $53.22 | $63.5 | $87.57 |
| Operating income | -$48.08 | -$51.28 | -$62.56 | -$28.59 |
| Income from continuing operations | ||||
| EBIT | -$44.12 | -$45.17 | -$52.76 | -$18.88 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$44.12 | -$45.17 | -$52.76 | -$18.88 |
| Income (for common shares) | -$44.12 | -$45.17 | -$52.76 | -$18.88 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $63.53 | $96.3 | $55.85 | $31.43 |
| Cost of revenue | ||||
| Gross Profit | $63.53 | $96.3 | $55.85 | $31.43 |
| Operating activities | ||||
| Research & development | $172.6 | $320.45 | $215.52 | $125.62 |
| Selling, general & administrative | $81.45 | $84.23 | $57.32 | $33.9 |
| Total operating expenses | $254.04 | $404.69 | $272.84 | $159.52 |
| Operating income | -$190.51 | -$308.39 | -$216.99 | -$128.09 |
| Income from continuing operations | ||||
| EBIT | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Income (for common shares) | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$44.12 | -$45.17 | -$52.76 | -$18.88 |
| Operating activities | ||||
| Depreciation | $4.88 | $4.74 | $4.47 | $4.19 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.47 | $10.1 | $12.9 | $10.98 |
| Total cash flows from operations | -$36.64 | -$38.27 | -$28.49 | -$28.86 |
| Investing activities | ||||
| Capital expenditures | -$0.18 | -$0.56 | -$2.2 | -$3.21 |
| Investments | $45.53 | $25.37 | $35.37 | $12.55 |
| Total cash flows from investing | $45.35 | $24.8 | $33.17 | $9.34 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.18 | $0.06 | $0.21 | |
| Net borrowings | ||||
| Total cash flows from financing | -$0.18 | $0.06 | $0.21 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $8.54 | -$13.47 | $4.73 | -$19.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Operating activities | ||||
| Depreciation | $18.28 | $13.76 | $5.85 | $3.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.46 | $78.73 | $54.36 | $30.75 |
| Total cash flows from operations | -$132.26 | -$248.21 | -$162.87 | -$39.23 |
| Investing activities | ||||
| Capital expenditures | -$6.15 | -$35.57 | -$50.7 | -$4.93 |
| Investments | $118.82 | $202.32 | -$273.32 | -$156.14 |
| Total cash flows from investing | $112.67 | $166.75 | -$324.02 | -$161.08 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.09 | $9.21 | $432.45 | $282.35 |
| Net borrowings | ||||
| Total cash flows from financing | $0.09 | $9.21 | $453.13 | $282.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$19.51 | -$72.25 | -$33.76 | $82.53 |
News
Fundamentals
| Market cap | $530.61M |
|---|---|
| Enterprise value | $577.10M |
| Shares outstanding | 98.63M |
| Revenue | $63.53M |
|---|---|
| EBITDA | -$142.65M |
| EBIT | -$160.93M |
| Net Income | -$160.93M |
| Revenue Q/Q | -96.22% |
| Revenue Y/Y | -34.03% |
| P/E ratio | -3.30 |
|---|---|
| EV/Sales | 9.08 |
| EV/EBITDA | -4.05 |
| EV/EBIT | -3.59 |
| P/S ratio | 8.35 |
| P/B ratio | 1.44 |
| Book/Share | 3.74 |
| Cash/Share | 0.58 |
| EPS | -$1.63 |
|---|---|
| ROA | -28.42% |
| ROE | -38.17% |
| Debt/Equity | 0.37 |
|---|---|
| Net debt/EBITDA | -0.57 |
| Current ratio | 8.48 |
| Quick ratio | 8.48 |